WELCOME TO

Specialist Communications for Life Sciences
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.

Our
Services
PR & Media
Strategic support to drive communications programmes and build visibility
Marketing
Effectively promote products and services to generate leads
Design & Branding
Elevate company image with bespoke design services for websites and corporate materials
Investor Relations
Strengthen relationships with investors through targeted outreach

The
Team
An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.
EVENTS
-
BIO-Europe 2026
-
ELRIG Protein Sciences in Drug Discovery 2026
-
Association of Molecular Pathology – Annual Meeting – 2026
-
Society for Neuroscience Annual Meeting 2026
BioUK acquires certain key assets of SEHTA to strengthen support for life science SMEs across the UK
Asset acquisition combines BioUK’s strength in biotech and therapeutics with SEHTA’s MedTech and HealthTech expertise, covering the full breadth of life science SMEs Enhances BioUK’s support offerings with SEHTA’s broad [...]
Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study
Retrospective study evaluated the efficacy and safety of HIVEC® with mitomycin C in patients treated at the Erasmus Medical Center and Amphia hospital between 2015 and 2022 Real-world data support [...]
Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial
Qureight’s Fibr8 model to provide structural assessment as secondary endpoint in Contineum’s Phase 2 PROPEL-IPF clinical trial examining the safety and efficacy of PIPE-791 in idiopathic pulmonary fibrosis (IPF) patients [...]
























